India Molecular Diagnostics Market By Application (Infectious Disease, Blood Screening, Genetic Testing, Oncology Testing), By Technology (PCR, In-situ Hybridization, Chips and Microarrays, Mass Spectrometry, Sequencing, Others), By End User (Hospitals, Academic & Reference Laboratories), By Region, Competition, Forecast & Opportunities, 2020-2030F

Market Overview

India Molecular Diagnostics Market was valued at USD 941.24 Million in 2024 and is expected to reach USD 1413.74 Million by 2030, growing at a CAGR of 7.12% during the forecast period.

Molecular diagnostics involves a wide range of advanced techniques used to analyze biological markers in the genome and proteome, enabling precise detection and measurement of disease-related genetic material. These methods support accurate diagnosis, disease characterization, treatment planning, and ongoing monitoring, making molecular diagnostics a critical component of modern healthcare. Techniques such as PCR, DNA sequencing, and in situ hybridization are widely used across applications including infectious diseases, oncology, genetics, and blood screening.

The market is expanding rapidly, driven by technological advancements and rising disease prevalence. For example, Siemens Healthineers received approval in 2024 to manufacture a Monkeypox RT-PCR detection kit in India, strengthening local diagnostic capabilities.

Key Market Drivers

Large Outbreaks of Bacterial and Viral Epidemics

Frequent bacterial and viral outbreaks are sustaining strong demand for molecular diagnostics in India because PCR, nucleic acid amplification, and next generation sequencing help laboratories detect pathogens quickly and accurately, which improves treatment decisions, supports contact tracing, and strengthens outbreak containment in a country that continues to invest in infectious disease surveillance.

This demand is being reinforced by public health infrastructure, as the government has approved 165 Virus Research and Diagnostic Laboratories across the country and has credited these facilities with sequencing viruses and validating nearly 1,700 diagnostic commodities, showing that molecular testing is now deeply embedded in India’s response capacity.

Genomic monitoring has also expanded through INSACOG, which began with 10 national laboratories and later grew to 28 laboratories to track genomic variations in SARS-CoV-2, improving India’s ability to watch for new variants and emerging pathogens. A strong industry example comes from Roche, whose cobas 8800 system launched in India can process 960 samples in 8 hours and about 3,000 in 24 hours, illustrating how large companies are adding high throughput molecular platforms that match the country’s need for accurate and scalable diagnostics.

Increasing Demand for Point-of-Care Diagnostics

The rising demand for point of care diagnostics is significantly boosting molecular diagnostics adoption in India because near patient testing brings rapid and reliable results closer to communities that have limited access to centralized laboratories, while nucleic acid based methods such as real time PCR support earlier detection and faster clinical decisions during both outbreaks and routine infectious disease management.

This shift accelerated after the COVID-19 period and continues to widen into chronic infectious disease management, as portable molecular platforms are now being used for tuberculosis, hepatitis, HIV, HPV, dengue, and other conditions that require accurate testing with quick turnaround in decentralized settings. India’s progress is especially visible in the Truenat platform developed by Molbio Diagnostics, which the World Health Organization endorsed for initial TB diagnosis and rifampicin resistance detection and which ICMR stated is already accepted under the National TB Elimination Programme, reinforcing the role of indigenous point of care molecular testing in public health delivery.

A strong supporting example comes from Molbio itself, which says Truenat can test more than 35 diseases and that 451 Truenat machines were launched across Uttar Pradesh, illustrating how local manufacturing and field deployable molecular systems are expanding access to fast and scalable diagnostics across India.

Rapidly Evolving Technologies

Rapid advancements in molecular diagnostic technologies are significantly driving adoption in India, as PCR, nucleic acid amplification tests, and next generation sequencing are giving clinicians higher precision, faster turnaround, and wider clinical utility, which makes these tools increasingly important for timely treatment decisions and stronger disease control during infectious outbreaks.

Their versatility across infectious diseases, oncology, and other high need areas is also expanding demand, and this is reflected in public sector capacity building through the DHR ICMR DIAMOnDS programme, which has established 24 institutes to provide advanced molecular oncopathology services and extend access to sophisticated diagnostics beyond a few top tier centres. Government backed integration of molecular testing into public health delivery, along with the spread of portable and automated systems, is making these technologies more accessible in clinics and decentralized settings rather than limiting them to large hospitals alone.

For instance, Roche’s cobas 8800 can deliver up to 960 results in 8 hours while Molbio says its Truenat platform supports testing for more than 35 diseases, showing how both multinational and domestic companies are scaling high throughput and field deployable molecular diagnostics for India’s evolving healthcare system.

Recent Advancements in Pharmacogenomics

Advancements in pharmacogenomics are significantly increasing demand for molecular diagnostics in India because personalized medicine now relies on genomic and precision diagnostic tools to show how genetic differences influence drug response, helping clinicians improve efficacy, reduce adverse effects, and make treatment decisions with greater confidence across cancer care and other complex disorders.

Improved accessibility and affordability of next generation sequencing and related molecular technologies are also making pharmacogenomic testing more feasible across healthcare settings, while the government’s GenomeIndia initiative has already completed whole genome sequencing data for over 10,000 individuals and the DHR ICMR DIAMOnDS network is extending biomarker based precision treatment through 25 centres, reinforcing the clinical and institutional foundation for wider adoption in India.

The pharmaceutical and diagnostics ecosystem is further strengthening this shift as genetic insights are increasingly used in research, companion diagnostics, and targeted therapy pathways, and for instance Thermo Fisher’s PharmacoScan solution supports about 4,500 targets across around 1,000 genes, illustrating the scale at which large companies are enabling pharmacogenomic analysis that can support more individualized treatment strategies in the Indian market.

Download Free Sample Report

Key Market Challenges

Limited Budgets for R&D and Economic Slowdown

Limited R&D budgets and economic slowdown are key challenges impacting the growth of molecular diagnostics in India. Insufficient funding for research restricts innovation, slowing the development of new diagnostic tests and improvements in existing technologies. This limits the availability of cost-effective and accessible solutions.

Economic pressures on healthcare systems and individuals further reduce adoption, as advanced molecular tests are often expensive compared to conventional alternatives. High capital investment and operational costs for setting up diagnostic laboratories also create barriers, particularly in resource-constrained regions.

To overcome these challenges, increased investment in R&D, infrastructure, and affordable technologies is essential. Government support, public-private partnerships, and innovative financing models can help improve accessibility and drive wider adoption of molecular diagnostics in India.

Need for High-complexity Testing Centers

The requirement for high-complexity testing centers is a key barrier limiting the growth of molecular diagnostics in India. Advanced techniques such as PCR and next-generation sequencing (NGS) require specialized laboratories, sophisticated equipment, and highly trained professionals, making them difficult to scale across all regions.

Many healthcare facilities, particularly in rural and underserved areas, lack the financial resources to establish and maintain such infrastructure. Additionally, there is a shortage of skilled personnel, including molecular biologists and laboratory technicians, creating further constraints on service expansion.

Centralized testing in major cities also leads to delays in diagnosis and treatment, discouraging adoption. To overcome these challenges, investments in infrastructure, workforce training, and decentralized testing models are essential to improve accessibility and drive demand for molecular diagnostics in India.

Key Market Trends

Rapid Technological Advancements

Rapid technological advancements, characterized by accuracy, portability, and cost-effectiveness, are expected to significantly impact India's molecular diagnostics market. As companies strive to stay ahead in this competitive landscape, they continually upgrade their products by implementing new techniques that deliver specific, precise results.

Notably, industry leaders such as Sigma-Aldrich Corporation and QIAGEN are at the forefront of developing a new range of molecular diagnostic techniques. These include innovative methods such as Transcription-Mediated Amplification (TMA) and Loop-Mediated Isothermal Amplification (LAMP), which are proving instrumental in diagnosing various tumors. The growing use of multiplex PCR technologies and real-time PCR equipment, such as QIAGEN's EpiTect Methyl II PCR for detecting DNA methylation, is expected to further propel the market during the forecast period.

With such advancements and continuous innovation, the molecular diagnostics market in India is poised for significant growth, offering improved diagnostic capabilities and contributing to the overall advancement of healthcare in the country.

Rising Geriatric Population

The geriatric population in India is not only rapidly increasing, but it is also expected to rise by 41% over the next decade, according to the Government of India National Statistical Office. This projection indicates that India's geriatric population, aged 60 and above, will reach a staggering 194 million in 2031, compared to 138 million in 2021. Among states, Kerala has the highest share of elderly people, at approximately 16.5%, followed by Tamil Nadu, Himachal Pradesh, Bihar, Uttar Pradesh, and Assam.

Aging has become a significant risk factor for various diseases, such as obesity and diabetes, which, in turn, substantially increase the vulnerability to infectious diseases. For instance, the geriatric population is more susceptible to infectious diseases like COVID-19 due to factors such as decreased immune function, multimorbidity, and physiological changes associated with aging. Alarming statistics from the World Health Organization (WHO) indicate that, until April 2020, approximately 95% of COVID-19-related deaths were reported among patients aged 60 years or above. More than 50% of deaths occurred in patients aged 80 years or older. These figures underscore the urgent need to address the challenges posed by the growing aging population, which is driving the demand for diagnostics and significantly influencing the market's growth.

Segmental Insights

Technology Insights

In 2024, the PCR technology segment emerged as the leader in revenue share. The technology markets for In Situ Hybridization (ISH) and genetic sequencing are expected to experience a surge in demand over the forecast period, driven by several factors. ISH's market share is projected to grow at a compound annual growth rate (CAGR) of over 31% over the forecast period, driven by the rising number of individuals affected by cancer and the increasing need for early diagnosis.

During the COVID-19 pandemic, PCR diagnostics experienced significant demand, primarily due to collaborative efforts by public-private partnerships such as InDx. This initiative aimed to tap into the market's untapped potential by lowering the cost of RT-PCR testing, making it more accessible for widespread population testing. By supporting the rapid indigenous production of RT-PCR diagnostic test kits, this initiative enabled the manufacturing of over 1 million test kits per day. As a result of this remarkable undertaking, the cost of RT-PCR tests fell from USD 10 to USD 7 over just one year. These developments highlight significant advances and efforts in molecular diagnostics, particularly in PCR technology and its applications in critical situations such as the COVID-19 pandemic. The ongoing progress and innovation in this domain are expected to shape the future of diagnostic testing and profoundly impact healthcare outcomes worldwide.

Application Insights

Based on application, the infectious disease segment has emerged as the dominant force in the market, accounting for a significant share of revenue in 2024. Molecular diagnostics, serving as the cornerstone of medical diagnosis for viral, bacterial, and parasitic infections, play a crucial role in this arena. Notably, demand for respiratory infection molecular diagnostics has surged exponentially following the widespread transmission of SARS-CoV-2.

The market is being propelled by the increasing number of product launches within the infectious disease segment. A case in point is BD's April 2020 announcement of the launch of the SARS-CoV-2 test on its BD MAX System. With heightened automation capabilities and the ability to process a larger volume of samples, the demand for molecular diagnostic reagents and consumables is poised to soar, thereby bolstering the overall market growth. Meanwhile, oncology accounts for a significant share of the applications segment, driven by the rising incidence of cancer.

The field of oncology research and cancer drug discovery has witnessed remarkable advances in molecular diagnostics using specific biomarkers associated with major cancer-causing genes and their manifestations. The early identification of predictive biomarkers in molecular diagnostics not only enables early detection of cancer in affected patients but also facilitates the development of personalized medications tailored to their specific needs.

Download Free Sample Report

Regional Insights

The western region of India, particularly Maharashtra and Gujarat, is rapidly emerging as a major force in the Molecular Diagnostics Market. This dominance can be attributed to several factors that contribute to its success. The region boasts a robust, state-of-the-art healthcare infrastructure equipped with advanced diagnostic facilities, which facilitates the widespread adoption of molecular diagnostics. This infrastructure ensures that individuals have access to accurate and timely diagnostic services, further enhancing patient care.

There is a high level of awareness among healthcare professionals and the general population in the region about the benefits and applications of molecular diagnostics. Through extensive education and training programs, healthcare providers are well informed about the potential of molecular diagnostics for disease diagnosis, prognosis, and personalized treatment. The general population is increasingly recognizing the value of molecular diagnostics for early disease detection, leading to improved health outcomes.

The western region of India is home to many key market players in molecular diagnostics. This concentration of expertise and resources fosters collaborations and partnerships, facilitating the development and advancement of diagnostic technologies. The continuous exchange of knowledge and ideas among these market players propels the field forward, leading to innovative solutions and improved patient care. Overall, the western region of India continues to shape and reshape the landscape of molecular diagnostics. With its robust healthcare infrastructure, high level of awareness, and concentration of market players, the region remains at the forefront of advancements in diagnostic technologies. By leveraging these strengths, the western region of India is paving the way for the future of molecular diagnostics and improving patient care.

Recent Developments

• In March 2026, Co-Diagnostics said it had begun shipping PCR Pro instruments, Co-Dx PCR MTB test kits, and sample-preparation instruments to its Indian joint venture CoSara Diagnostics to initiate tuberculosis clinical performance studies in India. The company added that the PCR Pro instrument had already received CDSCO licensing for manufacture and sale as a medical-device instrument, and that the studies were part of the regulatory path toward Indian clearance for the TB molecular test. This was an important development for India’s molecular diagnostics market because it moved a collaboration-led TB testing platform closer to formal clinical validation and potential commercialization in a country that still carries about a quarter of global tuberculosis cases.
• In November 2025, Servier India partnered with MedGenome and Strand Life Sciences to launch a patient-centric biomarker testing initiative across India for IDH-mutated Acute Myeloid Leukaemia and Cholangiocarcinoma. The programme was designed to improve access to molecular testing by expanding biomarker-based diagnosis for these cancers, which are often underserved in routine testing pathways, and it positioned precision diagnostics more centrally in oncology care. This collaboration stood out because it tied a pharmaceutical company directly to Indian genomics laboratories to widen the practical use of advanced molecular diagnostics in real patient management.
• In September 2025, India launched an IVD validation portal at the National VRDL Conclave, while the Health Ministry highlighted ICMR’s collaboration with CDSCO to create standard protocols for in-vitro diagnostics. According to the minister’s remarks, the publicly available protocols were described as a world first, and the new portal was intended to make validation faster, more transparent, and more industry-friendly as several VRDLs were also being upgraded as medical-device testing laboratories. This mattered to molecular diagnostics because stronger validation standards and faster approval pathways can directly support the rollout of higher-quality PCR, genomics, and other assay-based diagnostic products in India.

Key Market Players

• Roche Diagnostics India Pvt Ltd
• Abbott India Ltd
• Qiagen India Pvt Ltd
• BioMérieux India Pvt Ltd
• Becton Dickinson Pvt Ltd
• Bio-Techne India Pvt Ltd
• Danaher India (DHR Holding India Pvt. Ltd.)
• Bio-Rad laboratories India Pvt.Ltd

Report Scope:

In this report, the India Molecular Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• India Molecular Diagnostics Market, By Application:

o   Infectious Disease

o   Blood Screening

o   Genetic Testing

o   Oncology Testing

• India Molecular Diagnostics Market, By Technology:

o   PCR

o   In-situ Hybridization

o   Chips and Microarrays

o   Mass Spectrometry

o   Sequencing

o   Others

• India Molecular Diagnostics Market, By End User:

o   Hospitals

o   Academic & Reference Laboratories

• India Molecular Diagnostics Market, By Region:

o   North

o   South

o   West

o   East

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the India Molecular Diagnostics Market.

Available Customizations:

India Molecular Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

India Molecular Diagnostics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]